Pharmaxis (PXS) Stock Overview

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

PXS Stock Information

Symbol

PXS

Address

20 Rodborough RoadFrenchs Forest, NSW 2086Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://www.syntaratx.com.au

Country

🇦🇺 Australia

Phone Number

61 2 9454 7200

Pharmaxis (PXS) Price Chart

Pharmaxis Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.021649121857494655	N/A
Market Cap	$14.19M	N/A
Shares Outstanding	655.62M	16.47%
Employees	70.00	N/A
Shareholder Equity	9.56M	-11.52%

Valuation	2023	Change
P/S Ratio	3.64	N/A
P/B Ratio	1.48	N/A

Growth	2023	Change
Return on Equity	-0.8040	N/A

Earnings	2023	Change
Revenue	$3.90M	N/A
Earnings	-$7.69M	N/A
Gross Margin	0.5306	N/A
Operating Margin	-4.39	N/A
Net income margin	-1.97	N/A

Financial Strength	2023	Change
Total Assets	$16.25M	N/A
Cash on Hand	$6.24M	N/A
Debt to Equity	$1.02	13.69%
Current Ratio	$2.33	-26.26%